What is the success rate of Breyanzi?
Everyone will respond differently to Breyanzi (lisocabtagene maraleucel), and the success rate for someone else may be different than for you. Based on clinical trial data, the complete response rate in patients taking Breyanzi is around 20% to 73%, depending on the condition being treated.
Below, we will review the complete response rate in patients taking Breyanzi for certain kinds of lymphoma and leukemia. Keep in mind that some patients in the studies below had a partial response to treatment.
Large B-cell lymphoma
Breyanzi was studied in over 250 adults with refractory or relapsed B-cell lymphoma in a multicenter clinical trial. The study showed that after treatment with Breyanzi, the complete remission rate was 54%. Response to treatment was based on the 2014 Lugano criteria.
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
The complete response rate among patients who took Breyanzi for relapsed or refractory CLL or SLL in a clinical trial called TRANSCEND-CLL was 20%. A total of 65 patients were treated with Breyanzi in the study. Response to treatment was based on the 2018 International Workshop CLL (iwCLL) criteria.
Related questions
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- What is the difference between Truxima and Rituxan?
- Does Truxima make you gain weight?
Follicular lymphoma
In the TRANSCEND-FL clinical trial, adults with relapsed or refractory follicular lymphoma who took Breyanzi had a complete response rate of 73.4%. A total of 94 patients that were treated with Breyanzi were included in the final results. In order to be considered to have complete response, patients who did not have a negative bone marrow biopsy between their most recent disease progression and before starting lymphodepleting chemotherapy were required to have a negative bone marrow biopsy.
Mantle cell lymphoma
Out of 68 patients with relapsed or refractory mantle cell lymphoma who were treated with Breyanzi in the TRANSCEND-MCL trial, 67.6% saw a complete response. Response to treatment was based on 2014 Lugano classification.
Follow up with your healthcare provider if you have more questions about the success rate of Breyanzi.
References
Breyanzi [package insert]. Updated May 2024. Juno Therapeutics, Inc. Accessed August 6, 2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed
U.S. Food and Drug Administration. 2021. FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma. Accessed August 6, 2024 at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-or-refractory-large-b-cell-lymphoma
U.S. Food and Drug Administration. 2024. FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma
U.S. Food and Drug Administration. 2024. FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma
Read next
What is the survival rate of Kymriah?
Studies are ongoing to monitor the survival rate of patients who received Kymriah (tisagenlecleucel) as a cancer treatment. Currently, the available data shows the survival rate is 87.7% for patients with relapsed or refractory follicular lymphoma at 24 months after the Kymriah infusion, and 43.6% for patients with aggressive B-cell non-Hodgkin’s lymphoma. The 5-year survival rate for patients with advanced B-cell advanced B-cell acute lymphoblastic leukemia is 55%. Continue reading
What is the cost of Kymriah?
Kymriah (tisagenlecleucel) is an expensive CAR-T cell cancer therapy costs over $612,000 for one treatment infusion, but most people do not pay this amount. In addition, the Centers for Medicare & Medicaid Services (CMS) states that CAR-T cell therapy would be covered for eligible people with Medicare. Continue reading
What is Zydelig used for and how does it work?
In the United States, Zydelig is approved to treat relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab, where rituximab is appropriate to use taking into account other health conditions a person may have. Continue reading
Related medical questions
- What are the names of the BTK inhibitors?
- What's the difference between Kymriah and Yescarta?
- What is the success rate of Epkinly?
- What is the difference between Rituxan and Rituxan Hycela?
- How is Rituxan Hycela administered?
- What type of drug is Copiktra?
- What type of drug is Yescarta (axicabtagene ciloleucel)?
- Prednisone: What are 12 Things You Should Know?
- What causes infusion reactions to rituximab?
- What is the success rate of Monjuvi?
- How does Monjuvi work?
- How is Monjuvi given / administered?
- Is Velcade a type of chemotherapy?
- How much does Tecartus cost?
- Does ibrutinib cause hair loss?
- How long does Velcade stay in your body?
- How long does it take for Jaypirca to work?
- Is Tecartus a one-time treatment?
Drug information
- Breyanzi Information for Consumers
- Breyanzi prescribing info & package insert (for Health Professionals)
- Side Effects of Breyanzi (detailed)
Related support groups
- Breyanzi (1 questions, 3 members)
- Follicular Lymphoma (15 questions, 15 members)
- Diffuse Large B-Cell Lymphoma (14 questions, 3 members)
- Mantle Cell Lymphoma (10 questions, 9 members)
- Chronic Lymphocytic Leukemia (CLL) (26 questions, 57 members)
- B Cell Lymphoma (5 questions, 3 members)
